Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Summer 2015

Multiple Myeloma
Matthew Crowley
Otterbein University, matthew.crowley@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Hemic and Lymphatic Diseases Commons, Medical Pathology Commons, and the Nursing
Commons

Recommended Citation
Crowley, Matthew, "Multiple Myeloma" (2015). Nursing Student Class Projects (Formerly MSN). 98.
https://digitalcommons.otterbein.edu/stu_msn/98

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

Multiple Myeloma
Matthew Crowley BSN, RN
Otterbein University, Westerville, Ohio
Introduction
Multiple myeloma a rare and largely
incurable malignant disease the affects
the plasma cells. (Bilotti, Gleason,
McNeill, and the International Myeloma
Foundation Nurse Leadership Board,
2011). Understanding the
pathophysiology of Multiple Myeloma
(MM) and treatment options in Oncology
and Hematology nursing can be difficult.
It is the goal of this poster to outline the
pathophysiology, prognosis, treatment
options available to multiple myeloma
patients.
Multiple myeloma accounts for about
10% of hematologic malignancies in the
U.S. (Kuo, Fenves, Mehta, 2011). MM is
the second most common hematologic
malignancy with twenty-four thousand
new MM cases each year (Bianchi, and
Anderson, 2014 )

Signs & Symptoms
• Bone pain and fractures
• Fatigue
• Increased infections
• Weakness and fatigue
• Restlessness
• Confusion
• Increased thirst
• Nausea and vomiting
• Loss of appetite weight
loss
• Impaired kidney function
• Increased or decreased
urination

Pathophysiology

Implications for Nursing Care

In normal physiology mature plasma
cells make up less than 5% of the bone
marrow cells. Precursor cells
plasmablasts and B lymphocytes are
stimulated by antigens and cytokines then
migrate to the bone marrow where they
stop proliferating and begin to
differentiate to mature plasma cells
(Mangan, 2005). The majority of MM is
preceded by a premalignant disease
known as monoclonal gammopathy of
undetermined significance (Manier, Sacco,
Leleu, Ghobrial, and Roccaro, 2012). This
monoclonal neoplasm results in the
expansion of a single clone of plasma cells
(Ferreira, 2013). The monoclonal cells
crowd out healthy cells.
Unregulated proliferation of
monoclonal plasma cells accumulate in
the marrow which leads to secretion of
cytokines by the tumor cells. Here in the
microenvironment of the bone marrow
the ability of myeloma to live and
replicate is thought to occur (Mangan,
2005).
The majority of MM patients eventually
relapse with all therapeutic options
currently available (Lawasut, Groen,
Dhimolea, Richardson, Anderson, and
Mitsiadesa, 2013).
Balance between bone resorption and
new bone formation is lost in many cases
of MM, resulting in bone destruction and
the development of osteolytic lesions
(Mainer et al., 2012) Bone health is a
primary concern for MM patients.

Treatment options include the use of
monoclonal antibodies against specific
surface molecules in MM cells (Lawasut et
al., 2013). High-dose chemotherapy with
autologous stem cell transplantation is the
standard of therapy for patients newly
diagnosed with multiple myeloma who are
younger than age 70 or have no
comorbidities (Tariman, and Estrella, 2005).
Nursing care occurs in multiple settings.
“Nurses provide care and education to
patients at all stages of the multiple myeloma
(MM) disease continuum, from the
premalignant stage and diagnosis all the way
through survivorship and to the end of life.”
(Nicoletti, 2012) Patients present to routine
exams, present to emergency department
and as inpatients who are newly diagnosed.
Post diagnosis nursing care involves
treatment with chemotherapy, care in
medical surgical settings, survivorship, and
hospice.

Conclusion

http://healthresearchfunding.org

Fatigue is a commonly reported
symptom of MM often thought to be a
consequence of anemia (Booker,
Olson, Pilarski, Noon, and Bahlis,
2009). Anemia (mostly normocytic
normochromic) is seen in
approximately 75% of patients (AlFarsi, 2013)
http://www.keatslab.org/multiple-myeloma-info
http://www.moderncancerhospital.com/cancer/multiple-myeloma/

Multiple Myeloma diagnosis and
prognosis is viewed as incurable there
remains many treatment options based on
the stage of cancer, age and comorbidities.
Patient goals should always be considered
when developing treatment plans and
discussing options. Early stages of the
disease can yield many years of quality life
with current treatments ranging from
monoclonal therapies to bone marrow
transplant.
For end stage disease patients quality of life
can be achieved through compassionate
nursing care delivered by palliative
measures and hospice care
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